{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T07:31:15Z","timestamp":1772177475516,"version":"3.50.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chongqing Science and Health Joint Medical Research Project","award":["2024QNXM012"],"award-info":[{"award-number":["2024QNXM012"]}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Tocilizumab (TCZ) is widely used in the treatment of autoimmune diseases and usually needs to be combined with other drugs. However, limited evidence is available on TCZ drug\u2013drug interactions (DDIs). This study aimed to identify and evaluate the adverse events (AEs) associated with DDIs between TCZ and co-administered drugs based on real-world clinical data to offer a reference basis for clinical decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study was conducted to estimate the AEs related to DDIs between TCZ and three categories of drugs, including disease-modifying antirheumatic drugs (DMARDs), glucocorticoids, and non-steroidal anti-inflammatory drugs (NSAIDs). AE information for the target drugs from the first quarter of 2004 to the third quarter of 2025 was downloaded from the OpenVigil FDA data platform. The following four frequency statistical models were used to detect the AEs related to DDIs and to evaluate the correlation: the reporting ratio method, the \u03a9 shrinkage measure model, the combination risk ratio model, and the chi-squared statistics model. The influence of sex and age on the drug and the target AEs was analyzed using Pearson\u2019s chi-squared test and reporting odds ratios with 95% confidence intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eleven drugs were included for the analysis of AEs associated with TCZ combination therapy. A total of 824 AEs were detected by at least one of the four models; 35.6% (293\/824) AEs were significantly positively correlated with DDIs and were related to higher reporting rates of AEs than when used alone. Musculoskeletal and connective tissue disorders were the most frequently involved system organ class for TCZ-DMARD and TCZ-NSAID combinations. The most significant DDI-related AEs identified for specific TCZ drug combinations were as follows: with DMARDs (e.g., methotrexate, hydroxychloroquine, and leflunomide), occurrence of anti-cyclic citrullinated peptide (CCP) positivity, hand deformity, and pemphigus were observed; with glucocorticoids (specifically prednisone), pemphigus, hand deformity, glossodynia, and pericarditis should be monitored; with NSAIDs (specifically diclofenac), heightened vigilance is warranted for anti-CCP positive, rheumatic fever, duodenal ulcer perforation, and\n                      <jats:italic>Helicobacter<\/jats:italic>\n                      infections. Age and sex influence DDI risks: adults (\u226518\u202fyears) were more susceptible to infusion reactions with TCZ\u202f+\u202fhydroxychloroquine or TCZ\u202f+\u202fsulfasalazine, and to joint swelling with TCZ\u202f+\u202fnaproxen. Male patients demonstrated a higher incidence of stomatitis with TCZ\u202f+\u202fmethotrexate, and of joint swelling with TCZ\u202f+\u202fibuprofen or TCZ\u202f+\u202fnaproxen. Female patients were more susceptible to infusion-related reactions and infections with TCZ\u202f+\u202fdexamethasone, and to abdominal discomfort with TCZ\u202f+\u202fmethylprednisolone.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Healthcare providers should maintain vigilance of potential DDI-related AEs when TCZ is used in combination with DMARDs, glucocorticoids, or NSAIDs. Particular attention is suggested for signals of decreased treatment efficacy, which may be associated with the formation of anti-TCZ antibodies, and for musculoskeletal, cutaneous, and gastrointestinal events. Monitoring serological parameters (e.g., CRP and Anti-CCP), skin\/mucosal symptoms, and signs of infection is recommended during combination therapy to support medication safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1736592","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:24:45Z","timestamp":1772169885000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse events related to drug\u2013drug interactions in tocilizumab combination therapy: a retrospective analysis and clinical implications"],"prefix":"10.3389","volume":"13","author":[{"given":"Ben-nian","family":"Huo","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents\u2019 Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, People\u2019s Hospital of Chongqing Liangjiang New Area","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Immunology, Children\u2019s Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan-ge","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents\u2019 Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan-Huan","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents\u2019 Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-tao","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents\u2019 Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents\u2019 Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1470488","DOI":"10.3389\/fimmu.2025.1470488","article-title":"Update on tocilizumab in rheumatoid arthritis: a narrative review","volume":"16","author":"Parisi","year":"2025","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2165\/00003495-200969050-00007","article-title":"Tocilizumab: a review of its use in the management of rheumatoid arthritis","volume":"69","author":"Oldfield","year":"2009","journal-title":"Drugs"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.semarthrit.2020.05.013","article-title":"Serious adverse events in children with juvenile idiopathic arthritis and other rheumatic diseases on tocilizumab\u2014a real-world experience","volume":"50","author":"Aeschlimann","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e41552","DOI":"10.1097\/md.0000000000041552","article-title":"Therapeutic and hepatoprotective effect of tocilizumab combined with total glycosides of peony in systemic juvenile idiopathic arthritis","volume":"104","author":"Gao","year":"2025","journal-title":"Medicine"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/clpt.2011.35","article-title":"Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis","volume":"89","author":"Schmitt","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/art.38920","article-title":"An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy","volume":"67","author":"Rao","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/acr.24384","article-title":"Functional ability and health-related quality of life in randomized controlled trials of tocilizumab in patients with juvenile idiopathic arthritis","volume":"73","author":"Brunner","year":"2021","journal-title":"Arthritis Care Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e2511095","DOI":"10.1001\/jamanetworkopen.2025.11095","article-title":"Tocilizumab monotherapy or combined with methotrexate for rheumatoid arthritis: a randomized clinical trial","volume":"8","author":"Liu","year":"2025","journal-title":"JAMA Netw Open"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/art.40176","article-title":"Transaminase levels and hepatic events during tocilizumab treatment: pooled analysis of long-term clinical trial safety data in rheumatoid arthritis","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1111\/bcp.14868","article-title":"Pharmacovigilance-based drug repurposing: the search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections","volume":"87","author":"B\u00f6hm","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/pds.3805","article-title":"Standardisation of the FAERS database: a systematic approach to manually recoding drug name variants","volume":"24","author":"Wong","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1292163","DOI":"10.3389\/fphar.2024.1292163","article-title":"Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events","volume":"15","author":"Huo","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA\u2014inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"24955","DOI":"10.1038\/srep24955","article-title":"Systematic analysis of adverse event reports for sex differences in adverse drug events","volume":"6","author":"Yu","year":"2016","journal-title":"Sci Rep"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nbt.2113","article-title":"OpenVigil-free eyeballs on AERS pharmacovigilance data","volume":"30","author":"B\u00f6hm","year":"2012","journal-title":"Nat Biotechnol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jsps.2013.02.003","article-title":"Factors affecting the development of adverse drug reactions (review)","volume":"22","author":"Alomar","year":"2014","journal-title":"Saudi Pharm J"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"981","DOI":"10.2165\/00002018-200528110-00002","article-title":"Perspectives on the use of data mining in pharmaco-vigilance","volume":"28","author":"Almenoff","year":"2005","journal-title":"Drug Saf"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1080\/14740338.2024.2382227","article-title":"Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study","volume":"23","author":"Hu","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00784-020-03299-0","article-title":"Taste disorder\u2019s management: a systematic review","volume":"24","author":"Braud","year":"2020","journal-title":"Clin Oral Investig"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S0140-6736(11)61171-9","article-title":"Rheumatic heart disease","volume":"379","author":"Marijon","year":"2012","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13075-017-1401-2","article-title":"High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study","volume":"19","author":"Takeuchi","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.3899\/jrheum.091432","article-title":"Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter?","volume":"37","author":"Jawaheer","year":"2010","journal-title":"J Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1586\/1744666X.2014.926219","article-title":"The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences","volume":"10","author":"Keiserman","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2008.092866","article-title":"Long-term safety and efficacy of TCZ, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study","volume":"68","author":"Nishimoto","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double\u2010blind randomized controlled clinical trial of the interleukin\u20106 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/annrheumdis-2019-215987","article-title":"Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab","volume":"79","author":"Shafran","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/bcp.13500","article-title":"Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis","volume":"84","author":"Bastida","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2146\/ajhp070449","article-title":"TCZ: the first interleukin-6-receptor inhibitor","volume":"65","author":"Sebba","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/jcpt.12456","article-title":"Tocilizumab-induced pancreatitis: case report and review of data from the FDA adverse event reporting system","volume":"41","author":"Flaig","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"bcr2012007413","DOI":"10.1136\/bcr-2012-007413","article-title":"Three cases of severely disseminated Staphylococcus aureus infection in patients treated with tocilizumab","volume":"2013","author":"Nguyen","year":"2013","journal-title":"BMJ Case Rep"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s10165-010-0279-5","article-title":"Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions","volume":"20","author":"Nishimoto","year":"2010","journal-title":"Mod Rheumatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1161\/CIRCULATIONAHA.117.029233","article-title":"Reality and truth: balancing the hope and the hype of real-world evidence","volume":"136","author":"Patel","year":"2017","journal-title":"Circulation"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1736592\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:24:46Z","timestamp":1772169886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1736592\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":34,"alternative-id":["10.3389\/fmed.2026.1736592"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1736592","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"article-number":"1736592"}}